CNBC - RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

Hims stock price growth 25% since the peptide meeting day is set

KEY POINTS 

* Investors are starting to focus on what will replace compounded GLP-1 as a growth driver for telehealth companies like Hims & Hers Health. 
* Peptides are gaining attention as a potential new growth vector, despite clinical evidence for efficacy being limited.
* The FDA review process is only just beginning, with a Pharmacy Compounding Advisory Committee meeting scheduled for July 2026.

Full link: [https://www.cnbc.com/amp/2026/04/16/rfk-jr-peptides-hims-hers-glp-1.html](https://www.cnbc.com/amp/2026/04/16/rfk-jr-peptides-hims-hers-glp-1.html)